| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3199692 | Journal of Allergy and Clinical Immunology | 2011 | 11 Pages |
Abstract
This integrated analysis supports and expands on the results of the phase 3 studies. Ecallantide appears to be effective and well tolerated for the treatment of HAE attacks.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Albert L. MD, Marilyn MS, Robyn J. MD, H. Henry MD, PhD, Patrick T. MD, PhD, William E. MD,